Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,442,820.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the sale, the director owned 366,682 shares in the company, valued at $88,176,020.54. This represents a 1.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of JAZZ stock opened at $248.25 on Thursday. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $249.64. The stock has a market cap of $15.60 billion, a price-to-earnings ratio of -12,406.30, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The firm has a fifty day moving average of $231.22 and a 200-day moving average of $197.12.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion for the quarter. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Cardinal Capital Management raised its position in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock worth $2,471,000 after acquiring an additional 66 shares during the last quarter. Bessemer Group Inc. increased its position in Jazz Pharmaceuticals by 0.3% in the first quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company’s stock worth $4,228,000 after purchasing an additional 73 shares during the period. UMB Bank n.a. increased its position in Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 81 shares during the period. Pinnacle Associates Ltd. raised its holdings in Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock worth $1,905,000 after purchasing an additional 83 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC raised its holdings in Jazz Pharmaceuticals by 4.4% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,996 shares of the specialty pharmaceutical company’s stock worth $377,000 after purchasing an additional 85 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on JAZZ. Royal Bank Of Canada increased their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Bank of America increased their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Leerink Partners upped their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a report on Wednesday, April 22nd. Finally, Morgan Stanley reiterated an “overweight” rating and set a $245.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $245.94.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.